Adtec Healthcare Limited was founded from Adtec Plasma Technology Japan, a company recognised as a global pioneer in plasma innovation for more than 40 years. With deep scientific roots and a long-standing commitment to advancing plasma science, Adtec laid the foundation for groundbreaking medical applications that would later transform infection management and wound care. Drawing on decades of research, engineering excellence, and clinical collaboration, Adtec Healthcare was established to bring these innovations directly into the healthcare environment.
A defining milestone in the company’s history was the introduction of the world’s first clinical trials using the Adtec MicroPlaSter for the treatment of chronic wounds. At a time when antibacterial resistance and hard-to-heal infections were becoming increasingly urgent global challenges, Adtec Healthcare demonstrated both vision and scientific leadership. These early trials validated the potential of plasma-based therapies in real clinical settings and positioned the company at the forefront of a new approach to infection management—one that does not rely on antibiotics or traditional conventional therapies.
Since those pioneering clinical trials, Adtec Healthcare has continued to refine and advance its technology, leading to the development of the SteriPlas Premium Cold Plasma. This next-generation innovation represents a significant shift in how infections are treated and managed. Unlike conventional methods, the SteriPlas works at low temperatures, making it safe for direct application to human tissue while remaining highly effective against a broad spectrum of bacteria, including those protected within biofilm.
Today, the SteriPlas is setting a new standard in infection care and is used in hospitals and clinical settings around the world. Its growing adoption reflects both its clinical effectiveness and its strong safety profile. The Premium Cold Plasma technology is supported by more than 10,000 documented treatments, demonstrating consistent performance across a wide range of medical applications. In addition, over 90 peer-reviewed scientific publications provide robust evidence of its efficacy, mechanisms of action, and clinical value.
Crucially, the SteriPlas Premium Cold Plasma is backed by more almost two decades of safe clinical use, offering healthcare professionals confidence in its reliability and long-term safety. This extensive clinical history underscores Adtec Healthcare’s commitment to evidence-based innovation and patient-centred care. Rather than introducing technology for technology’s sake, the company prioritises solutions that are practical, safe, and capable of making a meaningful difference in everyday clinical practice.
Looking ahead, Adtec Healthcare remains dedicated to advancing infection management through continued research, clinical partnerships, and technological development. Through Premium Cold Plasma, Adtec Healthcare is not only redefining infection care today but also shaping a future where safer, more effective treatments are accessible worldwide.
